To the full analysis
AxoGen stock: growth
AXGNAxoGen reported $225.21M in revenue for fiscal 2025, up 20.2% on the prior year, up 14.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
48.3%
per year from 2006 to 2025, per share 30.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 14.9% | 23.5% | 48.3% |
| Revenue per share | 11.7% | 16.7% | 30.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $126.66K | −$367.18K | −$28.79K |
| 2007 | $100.43K | −$748.98K | −$466.95K |
| 2008 | $72.71K | −$1.04M | −$500.08K |
| 2009 | $24.91M | $15.05M | $15.43M |
| 2010 | $91.27K | −$1.32M | −$2.47M |
| 2011 | $4.85M | −$9.22M | −$7.17M |
| 2012 | $7.69M | −$9.42M | −$8.79M |
| 2013 | $10.95M | −$14.56M | −$10.69M |
| 2014 | $16.82M | −$17.71M | −$11.05M |
| 2015 | $27.33M | −$13.36M | −$13.61M |
| 2016 | $41.11M | −$14.41M | −$12.39M |
| 2017 | $60.43M | −$10.45M | −$10.53M |
| 2018 | $83.94M | −$22.4M | −$24.47M |
| 2019 | $106.71M | −$29.12M | −$25.1M |
| 2020 | $112.3M | −$23.79M | −$32.22M |
| 2021 | $127.36M | −$26.99M | −$41.81M |
| 2022 | $138.58M | −$28.95M | −$37.32M |
| 2023 | $159.01M | −$21.72M | −$20.63M |
| 2024 | $187.34M | −$9.96M | $11K |
| 2025 | $225.21M | −$15.7M | −$2.93M |
Revenue by region
Where AxoGen, Inc. generates its revenue.
- United States$222.4M99%
- Outside the US$2.8M1%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $222.44M | 98.8% |
| Outside the US | $2.77M | 1.2% |
| Total revenue | $225.21M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.